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1 Introduction
The Third Science and Technology Basic 
Plan[1], initiated in fiscal year 2006, primarily 
emphasizes the importance of technological 
innovation. It also emphasizes the importance of 
interdisciplinary and consolidated research, also 
emphasized in the previous term, and holds the 
collaboration between medicine and engineering 
to be a high-priority issue.
In Japan, the rapid aging of the population 
and the declining birthrate wil l eventual ly 
create a serious social issue: the lack of a young 
labor force. To address this issue, the “Revised 
Law concerning Stabilization of Employment 
of Older Persons” was enacted in fiscal year 
2006, extending the mandatory retirement age 
to slow the reduction of the labor force and 
reduce national pension expenses. The success 
of this policy relies on the health and longevity 
of older people so that they can continue on the 
job. Moreover, the maintenance of people’s good 
health, regardless of their age and sex, should 
reduce the nation’s continuously increasing 
medical expenditure. Most of all, if we consider 
the basics of life, to stay healthy, i.e. to be free of 
diseases, is a fundamental need for anyone who 
seeks to live a happy life.
O v e r  t h e  p a s t  f e w  d e c a d e s ,  J a p a n  
h a s  m a i nt a i ned  i t s  s t rong  i nte r n at ion a l  
compet it iveness  a s  a  nat ion excel l i ng at  
“manufacturing things” such as automobiles, 
machinery, electric and electronic appliances 
and mater ia ls [1, 2 ].  The countr y i s  a l ready 
equipped with a high technology development 
capacity, which is one of the requirements for 
satisfying the social need for developing medical 
equipment. Today, the global and Japanese 
markets for medical equipment are estimated 
as approximately twenty trillion yen and two 
trillion yen, respectively. The values of Japanese 
imports and exports in this area were about the 
same in fiscal year 1992, but the value of  imports 
has increased rapidly since then, reaching 955 
billion yen in 2004 and far exceeding the value of 
exports (430 billion yen) for the same year[3].
In domestic and international road maps, the 
development of molecular imaging technology is 
regarded as the next step after the completion of 
the Human Genome Project, a step that should 
contribute to the establishment of molecular 
libraries and ultimately to the promotion of 
molecular therapy and preventive medicine[4, 5]. 
The promotion of col laborative innovation 
between medicine and engineering is crucial to 
the implementation of this road map and should 
be regarded as a top-priority issue in Japan.
The present report focuses on OCT (Optical 
Coherence Tomography)[6], a growing technology 
whose development illustrates the perils and 
promises of this trend. The first patent for such 
an invention was applied for in Japan by a local 
university at the peak of the bubble economy in 
the late 1980s[7]. Even back then, the technology 
gave a glimpse of its potential to create business 
opportunities through its application to medical 
equipment, but Europe and the U.S., although 
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latecomers in OCT invention, have unfortunately 
gone far ahead of us in commercialization of the 
technology.
In Japan, the Law for Promoting University-Industry 
Technology Transfer (TLO law) went into force 
in 1998. The Third Science and Technology Basic 
Plan[1], approved at a Cabinet meeting in March 
2006, notes that “S&T system reforms enabled 
steady progress in industry-academia-government 
collaboration such as: increase in the numbers of 
industry- academia joint research, technology 
transfers by technology licensing organizations 
(TLOs), and university-derived ventures (the total 
number of such ventures has reached 1,000),” and 
that “in order for the activities of industry-academ
ia-government collaboration to achieve sufficient 
results, it is necessary to further revitalize the 
activities of university intellectual property 
centers and TLOs and make them more effective,” 
suggesting that measures for promoting university 
startups have already been taken. However, if 
such measures had been taken a decade earlier, 
i.e. before the bubble economy in late 1980s, 
and the significance of public investment in 
technological innovation had been recognized 
earlier, Japan would have had an advantage over 
Europe and the U.S. in the development and 
commercial exploitation of medical equipment.
Given these situations, we have reaffirmed 
the significance of the TLO Law and recognized 
the necessity of examining the current and 
future state of technology development in Japan, 
i.e. whether the development of technology 
(including OCT) synchronizes with the trend of 
technology transfer promotion and whether there 
is any obstacle to its future progress. Moreover, as 
is pointed out by the Ministry of Health, Labour 
and Welfare[8], we need to expose any operational 
problems in the clinical trial system or other 
systems related to the Pharmaceutical Affairs 
Law that are part of the approval process for new 
medical equipment products, as such problems 
may demotivate entrepreneurs and ultimately 
impair Japan’s global competitiveness in medical 
equipment development.
The Third Science and Technology Basic 
Plan[1] envisions that  “the core strategies are: 
development of human resources who can 
produce excellent research findings, creation of a 
competitive environment,  promotion of science, 
and creation of persistent innovations through 
strategic investment; and removal of systematic or 
operational obstacles to return the R&D benefits 
to society. Science and technology has a mission 
to address a broad range of these policy issues for 
the next five years,” emphasizing the importance 
of evaluating success in terms of concrete results.
From these standpoints, this report focuses 
on the appl icat ion of OCT to ophtha lmic 
diagnostic imaging systems and chronologically 
compares its developmental process in Japan 
and in western countries, from its invention to 
its commercialization. Moreover, this report 
introduces the attempt of industry-academia-g
overnment cooperation in Japan to recover the 
initiative, not only in first-generation but also in 
second- and third-generation OCT technology, 
and proposes some measures to promote 
collaborative innovation between medicine and 
engineering in Japan.
2 Principles underlying OCT
 and the course of
 its development
2-1 Principles underlying OCT
OCT i s  a  tech nolog y der ived f rom the 
Michelson interferometer, and its mechanism is 
roughly described in Figure 1[6]. The light source 
is a current-injection type semiconductor light 
source called an SLD (Super Luminescent Diode), 
which is an infrared light with a wavelength of 
















Prepared by the STFC based on Reference[6]
Figure 1 : Mechanism of OCT
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can penetrate 1-2 mm deep into a living body and 
that has a sufficiently high spatial coherence but 
a low temporal coherence. The beam is divided 
in two by a beam splitter; the transmitted beam 
reaches the surface of the test sample, enters the 
test sample and is reflected or scattered by any 
scattering object or by any boundary between 
materials with different refractive indices. This 
reflected or scattered beam returns to the beam 
splitter, where it is reflected to the photodetector 
as the object beam. Meanwhile, the beam initially 
reflected by the beam splitter is reflected by the 
reference mirror surface, passes through the 
splitter this time and reaches the photodetector 
interfering with the object beam based on the 
superposition principle.
When the path lengths (the distance traveled 
by the individual beams after being divided by 
the beam splitter until being combined again) of 
the object and reference beams are equal to each 
other (i.e. at zero path- length difference), the 
two waves intensify each other, and the intensity 
of the light received by the photodetector is 
greater than when the path- length difference 
is not zero. By performing such measurements 
with multiple reference -mirror positions and 
scanning the sample two - dimensionally and 
perpendicularly to the axis of the incident light, 
the laminar structure (boundaries of refractive 
indices) inside the sample can be displayed in a 
three-dimensional manner.
I f l ight with a high temporal coherence, 
e.g. a laser beam, is used as the light source, 
intensification of interference occurs irrespective 
of the path-length difference, making it difficult 
to see the laminar structure of the sample. Thus, 
the use of a light source with lower temporal 
coherence gives a higher depth resolution. This is 
the key to this invention, and the depth resolution 
can be 10 -20 µm, depending on the spectral 
bandwidth (about 50 nm) of the light source.
2-2 Process of development in Japan
The first patent on the principle of OCT was 
applied for in 1990 by Naohiro Tanno, who 
was then a Professor at Yamagata University[7]. 
An application was filed only for a Japanese 
patent and not for a U.S. or any other foreign 
patent. Meanwhile, the first research paper on 
OCT, titled “Backscattering Optical Heterodyne 
Tomography”[9] was prepared for the 14th Laser 
Sensing Symposium in 1991, and was written in 
Japanese and not in English. This reminds us of 
the famous story of Koichi Tanaka, the winner of 
the Nobel Prize for chemistry in 2002. Since Mr. 
Tanaka had never published any paper in English 
except for one that he wrote for a symposium 
held in China, his research had not received 
much international attention until he won the 
Prize. In earlier times, researchers did not have 
enough funds to publicize their discoveries to 
the world or to claim their intellectual property 
rights, and the importance of publishing research 
papers in English is here reacknowledged.
At that time, Professor Tanno was one of 
the key members of Biophotonics Information 
Laboratories, Ltd. (capitalized by the former 
Ministry of International Trade and Industry) 
led by Humio Inaba, who was then a professor 
at Tohoku University. The project was launched 
by researchers who were inspired by the idea 
of X- ray CT (Computer Tomography (theory 
by A l lan Cormack, apparatus by Godfrey 
Hounsfield)), which was awarded the Nobel 
Prize in Physiology or Medicine in 1979. They 
were seeking techniques to view the interior of 
human bodies or other organisms by detecting 
transmitted light using laser beams instead of 
X-rays.
In this project, professor Tanno proposed 
the idea of using in an interferometer a light 
source that retains one advantage of a laser 
light source, i.e. low spatial coherence, but has 
an intentionally reduced temporal coherence 
compared with a laser. Traditional interferometers 
Macula lutea
Optic disc
Figure 2 : Example of a retinal tomogram taken by OCT
Photograph provided by Microtomography Co., Ltd. 
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used l ight sources with low coherence in 
both temporal and spatial domains, such as 
incandescent lamps. However, an incandescent 
lamp is not a point source; it has width, i.e. has 
a low spatial coherence, and is thus incapable of 
providing a high resolution at the object plane. 
In practice, the resolution can be improved by 
placing a pinhole behind the incandescent lamp; 
however, this lowers the intensity, preventing the 
photodetector from catching enough light. OCT 
employs an interferometric measurement that 
takes advantage of the high spatial coherence and 
low temporal coherence of an SLD light source, 
which is the key feature of this invention.
Un l i ke  X - r ay  C T that  de tec t s  photons  
transmitted through an object, OCT detects 
the ref lected light and enables non- invasive, 
in -vivo imaging of the tissues in layers close 
to the sur face of a l iving body. Since this 
concept appeared to be too different from the 
original idea of utilizing the coherence of laser 
beams, which was the dominant focus in the 
Biophotonics Information Laboratories, Ltd., it 
was not accepted by some project members. As 
a result, the concept of OCT was never regarded 
as fundamental to the project, and a high 
priority was not placed on investigating potential 
applications of OCT such as medical equipment 
development.  Never theless ,  immediately  
after inventing OCT, Professor Tanno and his 
colleagues approached the Faculty of Medicine 
of Yamagata University and gave seminars 
several times a year to regularly introduce their 
technology seed from the engineering side.
The development process of OCT technology 
in Japan, from its invention to its application 
in medica l  equ ipment, i s  chronolog ica l ly 
shown in Table 1 along with that in Europe 
and the U.S. Professor Tanno continued to 
spread his technology seed by introducing 
OCT technology at the Yamagata Technopolis 
Foundation and suggesting to local companies 
the potential application of semiconductors to 
testing apparatus. However, in terms of actual 
research activity, since Yamagata University had 
no doctoral program then, he taught his master’
s students the methods of simulation and other 
calculation techniques. Although he published 
his first English paper[10] in 1994, he could not 
perform a full-scale demonstration experiment.
While Japan was in the middle of this “blank 
period”, in 1996, Zeiss - Humphrey Systems, 
Inc. (Humphrey), a U.S. subsidiar y of the 
well-established German optical firm Carl Zeiss 
Meditec AG (Carl Zeiss), released a test model 
of the industry’s first OCT equipment. Professor 
Shoji Kishi and his colleagues in the Faculty of 
Medicine of Gunma University showed an interest 
in this product and purchased the first model. 
They became the first group to collect clinical 
data in Japan and demonstrated its utility in the 
diagnosis of diseases of the ocular fundus[11].
Hearing this news, Professor Tanno noticed 
that the principle used in the OCT equipment 
was just what he had invented, and notified 
Carl Zeiss of this fact. With governmental 
suppor t based on the Law for Promoting 
University- Industry Technology Transfer (TLO 
law) enacted in May 1998, he received financial 
aid from JST ( Japan Science and Technology 
Agency) and started to make a prototype in 2000. 
In 2001, he received a visit from the CEO of 
Carl Zeiss for patent negotiation and persuaded 
the CEO to accept that his Japanese patent had 
preceded Carl Zeiss’s use of the technique. Carl 
Zeiss agreed to pay him a royalty on the use of 
the patent in Japan and to mark their domestically 
so ld  produc t s  w ith  the  Japa nese  patent  
number. Fueled by the success of the patent 
negotiation, Professor Tanno further promoted 
the development of the product; in 2001, the 
project was approved under the Temporary Law 
concerning Measures for the Promotion of the 
Creative Business Activities of Small and Medium 
Enterprises and received grants from the Tohoku 
Bureau of Economy, Trade and Industry and a 
Yamagata Prefecture New Industry Creative 
Type Technology R&D Grant. In 2002, then 
Professor Tanno, who had become the Chairman 
of the Cooperative Research Center of Yamagata 
University, founded Microtomography Co., 
Ltd., a venture capital firm jointly established 
by a semiconductor-manufacturing equipment 
manufacturer, MTEX Matsumura Corporation. 
He was appointed the director of the venture 
capital firm, and Sumio Matsumura and Michiro 
Hasegawa were appointed the CEO and the 
director, respectively. In 2003, the product was 
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Table 1 : Comparison of OCT development processes in Japan, Europe and the U.S.
Year
Japan Europe-U.S. 
Engineering Medicine Medicine-engineering collaboration
1990 Professor Tanno applied for Japanese patent
1991
Professor Tanno introduced his idea at the Yamagata 
Technopolis Foundation, and taught the associated 
calculation methods in a master’s-level course, because 
the university offered no doctoral program
Professor Fujimoto applied for a 
patent, published an angiotomogram 
in Science.
1992 Biophotonics Information Laboratories, Ltd. was founded
Professor Fujimoto received $6 million 
from Zeiss-Humphrey Systems 
Inc. (a subsidiary of CZ in U.S.) for 
promoting collaboration with an 
image processing group and the Eye 
Center of the Lincoln Laboratory. He 
published a fundus photograph in ’
93 Opt. Lett.
1993
1994 Professor Tanno et al. published their first English paper
1995
1996
Professor Fujimoto et al. published a 
collection of clinical data. CZ made 




purchased the first model 
manufactured by CZ
1998 The TLO Law was enacted
Professor Kishi et al. 
reported clinical cases.
G. Hausler et al. of the University of 




Professor Yasuno et al. of University of Tsukuba published the FD-OCT method. 
Professor Tanno et al. took part in a regional collaborative research project and 
received grants from JST (MTEX Matsumura Corporation (MTEX), the parent 
company of the current MT)
Speed-up and multifunctionality of 
OCT were pursued. Development of 
next-generation OCT was promoted, 
e.g. blood flow measurement 
utilizing the Doppler effect
2001
Professor Tanno received a visit from the CEO of CZ for patent negotiation. MTEX 
was approved under the Temporary Law concerning Measures for the Promotion of 
the Creative Business Activities of Small and Medium Enterprises and received a 
Yamagata Prefecture New Industry Creative-type Technology R&D Grant
2002
MTEX received grants from the Tohoku Bureau of Economy, Trade and Industry. 
Microtomography Co., Ltd. was founded
2003 MT received approval under the Pharmaceutical Affairs Law
2004
MT shipped the first domestic funduscopy equipment. Professor Yatagai et al. 
launched the “ultrahigh-speed Fourier optical radar microscope for biometrics” project 
funded by JST
2005
NEDO project “eye fundus blood flow, internal disease examination project” (Kyoto 
University, Yamagata Technopolis Foundation, Topcon, Nidek, Hamamatsu Photonics) 
was launched. Professor Yatagai et al. launched “the study concerning application of 
OCT to ophthalmology” through technological cooperation with Topcon Corporation.
CZ’s market share of first-generation 
OCT equipment reached 90%
2006
MT proposed the application of spectroscopic OCT to 3D tomography to in vivo 
oxygen saturation in cooperation with Professor Hidetoshi Yamashita of the Yamagata 
University Faculty of Medicine and Professor Tetsuya Yuasa of the Faculty of 
Engineering
MT: Microtomography Co., Ltd. CZ: Carl Zeiss Meditec AG
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approved under the Japanese Pharmaceutical 
Affairs Law, and in 2004, 14 years after the 
technology was invented and eight years later 
than its commercialization in Europe and the U.S., 
Japan’s first OCT equipment was finally put on 
the market.
2-3  Process of development in Europe and
 the U.S.
For comparison with the process described 
in Japan, this section explains the process of 
OCT development in Europe and the U.S., using 
Table 1. Professor J. Fujimoto and his colleagues 
at MIT[12], an institute famous as a base of 
industry- academia collaboration in the U.S., 
independently invented a principle similar to 
Professor Tanno’s invention. In 1991, they applied 
for a U.S. patent and published the world’s first 
English paper on OCT titled “Optical Coherence 
Tomography” in Science[13]. The term OCT 
currently used among experts around the world 
is derived from this paper. Professor Fujimoto 
launched a medicine-engineering collaboration 
project with an image processing group within 
MIT and medical scientists at the Eye Center of 
the Lincoln Laboratory. In 1993, they made the 
world’s first in vivo tomographic observation of 
the retina[14]. The professor received $6 million 
as a grant from Humphrey and vigorously worked 
on the commercialization of OCT equipment. 
In 1996, he took the initiative in publishing a 
5-cm-thick book of clinical data collected in trials 
of optical coherence tomographic imaging[15], 
which astonished ophthalmologists around 
the world. At about the same time, Humphrey 
released the world’s f irst test model of the 
equipment. Today, a decade after the product was 
first released, three companies are engaged in the 
production and distribution of the equipment, 
including the above-mentioned two companies 
and a latecomer, OPI (Opthalmic Technologies 
Inc.) of Canada. Carl Zeiss and its subsidiary 
Humphrey command 90% of global market share.
The speedy process of OCT development 
in Europe and the U.S. can be compared to a 
football game; the players cooperated in passing 
the ball (OCT) efficiently, from the defender, 
to the mid-fielder to the forward player, to take 
the shortest distance from the invention to the 
ultimate goal of market domination. The players 
comprehensively maintained a good balance 
between work- sharing and cooperation and 
worked swiftly to bring the university-launched 
innovation to practical use. The U.S. is already 
equipped with dynamic systems to facilitate 
collaborative innovation between medicine and 
engineering, i.e. the creation of technology seeds 
and swift technology transfer, and for collecting 
clinical data, systems that actually operate night 
and day. Researchers in Japanese universities 
and public institutions should learn from the 
smooth cooperation among industry, academia 
and government in the U.S. and should strongly 
support Japan’s original dynamic systems for 
facilitating collaborative innovation between 
medicine and engineering.
3 Institutional and operational
 problems of the system
This chapter focuses on the legal process in 
Japan that affects the speed of the collaborative 
innovation between medicine and engineering. 
Regarding the developmental process of medical 
equipment, i.e. R&D (invention) → prototype
→ clinical data collection → application →
screening under the Pharmaceutical Affairs Law
→ commercialization → shipment, the TLO 
Law is applied to the first half of the process; 
in the second half of the process, i.e. clinical 
data col lection and subsequent steps, the 
Pharmaceutical Affairs Law is applied to screen 
the products to be put on the market[16]. Although 
OCT is medical equipment, it is regarded as a 
pharmaceutical product and must be approved 
under the Pharmaceutical Affairs Law.
This also applies to the development of OCT 
equipment; preliminary clinical trials must be 
performed to collect clinical data demonstrating 
that the equipment is clinically effective and has 
no adverse effects. Clinical trials are accompanied 
by risks, which gives rise to issues of liability for 
accidents. Thus, screening must be performed 
with deliberation, requiring a vast amount of time 
and money. In the U.S., it only took five years for 
Professor Fujimoto and his colleagues to succeed 
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in the commercialization of the equipment; 
in Japan, it took 14 years from the invention 
to commercialization of the same technology. 
From now on, innovation based on collaboration 
between medicine and engineering must be 
advanced through comprehensive consideration 
of a variety of issues, e.g. those surrounding 
the facil itation of technology transfer from 
universities and the operational differences of the 
Pharmaceutical Affairs Law as it applies in Japan 
and the corresponding regulations in the U.S. For 
example, physicians and professors in the U.S 
have larger discretionary powers in the clinical 
trial process. If the physicians or professors 
consider that trials can be conducted safely, they 
are authorized to take the initiative in collecting 
clinical data on their own responsibility. This 
is why they can accumulate a large amount 
of clinical data to demonstrate the safety and 
efficacy of medical equipment within a short 
time.
In the case of this OCT equipment, Carl Zeiss 
submitted an application for approval under 
the Pharmaceutical Affairs Law, first in the U.S. 
and Europe and then in Japan. Following its 
successful development of the OCT equipment, 
the company also succeeded in commercializing 
OCT-based equipment for measuring the length 
of the eyeball and received approval under the 
Japanese Pharmaceutical Affairs Law before any 
other company. Meanwhile, Microtomography 
Co., Ltd. of Japan also developed a similar 
product and applied for the approval under the 
Pharmaceutical Affairs Law in November 2004 
as a generic machine using OCT equipment. 
However, the light source in Microtomography’s 
product had a wavelength of 830 nm[17], which 
was different from that in the Carl Zeiss product 
(780 nm),  so the company withdrew the 
application in March 2005 and re-applied for the 
machine as a new product in November 2005, 
and it still has not been approved as of June 2006.
Another typical case of medicine-engineering 
col laborat ion i s  a physician’s repor t of a 
therapeutic method for an intractable auditory 
disease[18]. The disease involves impairment 
of the cochlear duct, which is found between 
the eardrum and the auditory brain stem and 
which converts sound vibrations into neural 
signals. One technique to restore the auditory 
capability of patients affected by this disease 
is the transplantation of an artificial cochlea 
into the patient’s cochlear duct, which involves 
med ica l  t ech nolog y  deve loped  t h roug h  
medicine - eng ineer ing col laborat ion.  The 
artificial cochlea comprises a receiver and an 
electrode, which are placed inside the body, 
and a microphone, speech processor and a 
battery, which are placed outside the body. This 
procedure has been performed on more than 
sixty thousand people worldwide and more than 
four thousand people in Japan. Regarding this 
therapeutic method, Japan led the world at the 
development stage; however, it is reported that 
today the global market for the artificial cochlea 
is dominated by Australian, U.S., Austrian and 
French companies. This was reported in the 10th 
memorial lecture titled “Fusion between different 
fields and new research trends” given in the ME 
Forum hosted by the Science Council of Japan in 
cooperation with the Japanese Society for Medical 
and Biological Engineering (held on January 23, 
2006 in Sanjo Conference Hall at the University of 
Tokyo).
In this lecture, Mr. Yasuhiro Suzuki of the 
Health Policy Bureau, Ministry of Health, Labour 
and Welfare reported that “in cutting-edge basic 
technology, Japan is a world leader, along with 
the U.S. and European countries. Meanwhile, 
with respect to exploratory research on the 
application of such basic technology to novel 
medical equipment that satisfies clinical needs, 
as well as the infrastructure of clinical tests and 
trials using this equipment and the equipment 
screening system under the Pharmaceutical 
A f fa i r s  Law, Japan con f ronts  many more 
problems than Europe and the U.S.”[8] These 
countries have many judges for screening and 
approving new drugs or medical equipment. 
For instance, the U.S. FDA (Food and Drug 
Administration) has 9,000 judges, while its 
Japanese counterpart has only 300. In his report, 
Mr. Suzuki also acknowledged that “it is urgent 
that we improve the environment not only for 
basic and translational research but also for 
the clinical studies and trials that lie ahead. For 
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a long while the clinical trials system in our 
country has been “hollowed-out”, and as the 
environment for conducting clinical trials in 
other Asian countries is rapidly improving, the 
number of clinical trials conducted in our country 
is steadily decreasing. This not only deprives 
Japanese citizens of opportunities to benefit 
from leading-edge medical equipment but also 
directly decreases the global market share of 
domestic manufacturers.” He also acknowledged 
that “with the aim of drastically reforming the 
infrastructure for conducting clinical trials and 
studies in fiscal year 2006, the Ministry of Health, 
Labour and Welfare launched a ‘Research project 
for promoting establishment of infrastructure for 
clinical research’ with MHLW Grants-in-Aid for 
Scientific Research and performs a model project 
of a physician-driven clinical trial for improving 
the environment for secure accomplishment of 
clinical trials,” reflecting the Ministry’s active 
stance toward the operational improvement of 
the systems.
New drugs and medical equipment must all 
be approved under the Pharmaceutical Affairs 
Law, which reflects the strong public demand 
for product safety[19 -21]. In the White Paper on 
Labour Economy 2005[22], the Ministry declared 
its determination to “be deeply aware of our 
important duty to supply safe and effective 
drugs to the public and to protect people’s life 
and health from adverse effects of drugs or from 
defective drugs, and to exert our best efforts so 
that the disastrous health damage caused by such 
drugs will never occur again”.
Such assurance of safety seems incompatible 
with the swift action required for innovation. 
However, dealing with this severe contradiction 
is a top -priority issue confronted by every 
country, and Japan is no exception. In this 
sense, the above - mentioned report[8] from 
the Ministry of Health, Labour and Welfare 
suggests that “domestic development of superior 
medical equipment, collection of clinical data, 
swift screening of products and their clinical 
application are essential for the development of 
medical equipment. However, each of these steps 
is accompanied by risks and liabilities, and the 
quickest way to solve the problem of medical 
equipment development is to obtain a national 
consensus on how to deal with such risks and 
liabilities.” The primary purpose of medical 
equipment or drug development is the recovery 
and maintenance of health for patients and 
potential patients. The medical institutions and 
manufacturers are constantly demanded that they 
recognize their roles as suppliers of health, and 
without confusing the means with the ends, find 
transparent solutions acceptable to all.
To promote future collaborative innovation 
between medicine and engineering, we must 
explore measures to improve the operation of 
systems, such as expanding the discretionary 
powers of judges and ensuring the transparency 
of the screening process by giving access 
permission to research centers and research sites 
and bringing about more extensive disclosure of 
information concerning the screening process, 
etc., in addition to increasing the number of 
judges and building physician - driven, highly 
transparent systems for clinical trials. This would 
require an increase in the budget allocation to 
support the relevant departments in industry, 
universities and government. Moreover, for the 
mid - and long- term, we need to establish an 
interdisciplinary human resource development 
system between humanities and science to foster 
the development of people who are qualified 
both in the law and medicine or engineering and 
who are capable of making decisions at higher 
levels. Then we should be able to assign such 
people to the R&D of medical equipment or the 
screening process under the Pharmaceutical 
Affairs Law.
4 Next-generation OCT
4-1 Second-generation high-speed OCT
As discussed above, Japan can be credited 
as the first country in which OCT technology 
was patented. However, Japan lagged far behind 
others in the commercialization of OCT and 
is in a weak business position, at least for 
first-generation OCT. This section discusses the 
potential for Japan to catch up in the second and 
later generations of OCT.
Figure 3 can be compared to Moore’s Law for 
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semiconductors; it shows the annual progress 
in performance of OCT equipment, using the 
throughput speed of OCT as an index. The 
throughput speed in first-generation OCT was 
about 1Hz in 1991 at the laboratory level but 
increased to 4 kHz by 1999. However, after 
this 4,000 -fold increase, the throughput speed 
seemed to reach a saturation point. Meanwhile, 
regarding the medical appl ication of OCT 
equipment, there is a strong need to collect in 
vivo real - time tomograms as video data. As a 
result, the development of second-generation 
OCT involved a technology race to improve 
the throughput rate. The throughput rate has 
reached 200 kHz in recent models, and real-time 
recording and replay of 3D video data at video 
rates has been achieved at the product level.
The two most interest ing technolog ies 
for speeding up the equipment are FD - OCT 
( Four ier Domain OCT ) [23, 24 ] and SD - OCT 
(Spectra l  Domain OCT ) [25],  i n wh ich the 
number of moving par ts in the equipment 
is reduced. First - generation OCT provided 
three-dimensional tomograms by mechanically 
moving the reference mirror and the movable 
head comprising the optical interferometer, 
which limited measurement speed. Meanwhile, 
FD - OCT enables data gathering in the depth 
direction of the sample with the reference mirror 
fixed. The interference light obtained from the 
interferometer shown in Figure 1 is divided into 
wavelength spectra by a grating spectrometer 
and detected by a CCD (Charge Coupled Device) 
array, and the detected signal is subjected to 
real-time Fourier transformation by a computer to 
acquire the entire reflection intensity distribution 
in the depth direction substantial ly within 
one measurement[25]. Therefore, mechanical 
movement of the reference mirror can be 
omitted. Moreover, by exploiting the features 
of spatial collective parallel processing, which 
is an advantage of the optical system, and 
adopting one-dimensional imaging optics using 
a cylindrical lens, the uniaxial scanning of the 
sample plane can also be omitted. Furthermore, 
using a wavelength - tunable SLD light source 
means that spectrometers are no longer needed, 
which enables both speed-up and miniaturization 
of the equipment.
T he use  of  such h ig h - speed OC T that  
takes advantage of the more subtle features 
of light waves makes practical the real - time, 
three -dimensional observation of blood f low 
in the ocular fundus. Such R&D, exploiting 
the key characteristics of optical techniques, is 
being actively conducted by the Computational 
Opt ics Group led by Toyohiko Yataga i  of 
University of Tsukuba. During f iscal years 
2004 through 2007, the group is promoting 
research titled the “ultrahigh - speed Fourier 
opt ica l  radar microscope for biometr ics” 
with support from JST ( Japan Science and 
Technology Agency). The group is also engaged 
in technology transfer under industry-academia 
Figure 3 : Annual progress in the performance of OCT equipment
Prepared by the STFC based on reference data by Professor Yatagai
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col l aborat ion and s t a r ted a  s tudy of  the 
application of OCT to ophthalmology in fiscal 
year 2005 to promote commercialization of the 
next- generation high - speed OCT equipment 
th rough tech nolog ica l  cooperat ion with 
Topcon Corporat ion. Topcon Corporat ion 
has retained the largest share of the global 
market for conventional funduscopy equipment 
developed before OCT. The industry-academia 
col laboration in this case is simi lar to the 
relationship between Professor Fujimoto of MIT 
and Humphrey. With engineering -medicine 
collaboration, the university takes charge of the 
basic design of the equipment, the development 
of know-how for instrumentation and the patent 
application, while the company takes charge of 
the marketing and the legal process required for 
clinical trials and Pharmaceutical Affairs Law 
approval, utilizing its long-term experience and 
performance. The collection of clinical data in 
the university must be approved by the university’
s ethics committee, as has become obligatory 
since fiscal year 2005. Under the provisions of 
the TLO Law, University of Tsukuba sold the 
patent and the technical know-how concerning 
h ig h - speed OCT to  Topcon Cor porat ion 
and shared the profit from the sale with the 
inventor. In the case of high- speed OCT, the 
TLO Law functioned effectively, and the perils 
of the “Valley of Death” and the “Darwinian 
Sea” were successfu l ly navigated through 
industry-academia collaboration. In June 2006, 
the first high-speed OCT was commercialized by 
Topcon Corporation, and it is attracting attention 
for its potential to capture part of Carl Zeiss’s 
share of the entire OCT market in the future. 
Unfortunately, however, therapies using this 
equipment are not covered by insurance.
4-2 Various applications of OCT and
 the situation abroad 
 — toward the third generation —
It is well known that the progress of diabetes 
results in visual impairment. Microtomography 
Co., Ltd. has proposed a method for measuring 
the oxygen saturation in hemoglobin in the 
capillaries exposed on the retina by using OCT. 
Moreover, the Department of Ophthalmology of 
Kyoto University Hospital is cooperating with 
Yamagata Technopolis Foundation, Hamamatsu 
Photonics K.K., Topcon Corporation and Nidek 
Co., Ltd. to develop equipment for measuring 
the blood flow in the ocular fundus. The project 
has received a grant from the New Energy and 
Industrial Technology Development Organization 
(NEDO), and its success is expected to have a 
large impact. With the aim of improving the 
resolution of the ocular fundus tomogram up 
to the diffraction limit, the group is planning 
to adopt a method for collecting data while 
pe r for m i ng  rea l - t i me  mea su rement  a nd  
correction of ocular aberration, utilizing the 
adaptive optics techniques of Hamamatsu 
Photonics K.K., i.e. a liquid crystal spatial phase 
modulator.
So far, OCT technology has mainly been used 
in funduscopy equipment, but as the technology 
shifts into the third generation, its potential 
areas of application seem to be increasing, 
e.g. dermatology, dentistry, dental surgery, 
digestive surgery, cardiovascular surgery etc., 
in addition to its current implementation in 
ophthalmology. As an example of such new OCT 
technology, Professor Masamitsu Haruna of Osaka 
University[26] is developing an OCT that uses a 
light source with a wavelength of 1.3 or 1.5 µ
m. These wavelengths are absorbed by moisture 
and thus cannot be used for funduscopy, but can 
be applied to corneous or skin tomography or 
facial tomography applied to cosmetic product 
development, or can be combined with an 
endoscope for non-invasive tomography of the 
stomach wall. Moreover, with the attempt to 
understand the physiology of the living body, 
high-speed OCT is used to perform time-lapse 
photography, permitting dynamic observation of 
sweat glands and secretory glands[27]. Since this 
wavelength range is also used in optical fiber 
communication, companies including the former 
NTT have made a vast investment in relevant 
R&D. Achievements in cutting - edge devices 
such as light sources and photodetectors may be 
transferable to OCT equipment, including optical 
amplification by the multi-wavelength method or 
rare-earth-doped optical fibers.
The U.S. NIH (National Institutes of Health) 
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has drawn a road map in which the development 
of molecular imaging technology, which should 
contribute to the establishment of molecular 
libraries and ultimately to the promotion of 
molecular therapy and preventive medicine, 
is regarded as the next step fol lowing the 
completion of the Human Genome Project. 
Professor Fujimoto currently holds an additional 
post at NIH to explore the extension of OCT 
applications to molecular imaging. Meanwhile, 
Professor deBore and his colleagues, who left 
Professor Fujimoto’s group and moved to MGH 
(Massachusetts General Hospital), are working 
on the facil itation of medicine - engineering 
collaboration by taking advantage of high-speed 
OCT technology. Moreover, the University of 
California at Irvine has integrated the Schools 
of Medicine and Engineering and founded a 
medicine - engineering collaboration center, 
a facility similar to MGH. The establishment 
of such institutions in universities ref lects 
the accelerat ion of medicine - engineer ing 
collaboration in the U.S. Meanwhile, in Europe, 
Professor Fercher and his colleagues at the 
Medical University of Vienna, Austr ia, and 
Professor Drexler and his colleagues who left this 
group and moved to Imperial College, U.K., are 
actively engaged in the R&D of high-speed OCT 
technology.
As can be seen, the global competition to speed 
OCT innovation through medicine-engineering 
collaboration is becoming more and more intense. 
The competition is not only in the technical 
realm but also in the area of establishing systems 
to suppor t industr y - academia - government 
collaboration and the implementation of local 
equivalents of the Pharmaceutical Affairs Law. 
In the modern era of technology and business 
globalization, it is unavoidable that Japanese 
companies first perform clinical trials and receive 
product sales approval in the U.S. or Europe 
and then release the products in Japan. In order 
to stop this hollowing - out of clinical trials, 
as mentioned in the report by the Ministry of 
Health, Labour and Welfare[8], “we are working 
on the establishment of a registration system for 
clinical studies and an information disclosure 
system, following a global trend in which the 
contents of human studies such as cl inical 
trials, clinical studies, etc., must be notified to a 
third-party organization beforehand.” To further 
faci l itate col laborative innovation between 
medicine and engineering in Japan, it will be 
more important than ever to further exploit the 
TLO Law, and safely, swiftly and transparently 
implement the Pharmaceutical Affairs Law.
5 Conclusion
This report focused on OCT technology to 
illustrate the issues involved and the measures 
required to promote collaborative innovation 
between medicine and engineering from the 
standpoint of “strategic investment for the 
creation of innovations and removal of systematic 
or operational obstacles to return the benefits to 
society,” as required for the Third Science and 
Technology Basic Plan.
Funduscopy equipment typi f ies products 
d e ve l o p e d  w i t h  m e d i c i n e - e n g i n e e r i n g  
collaboration, and has demonstrated its power 
in the d iagnosis  of  g laucoma and ret ina l  
separation. The underlying principle, OCT 
(Optical Coherence Tomography) technology, was 
patented for the first time in Japan by Yamagata 
University in the late 1980s. As the first case of 
medicine -engineering collaboration, OCT had 
the potential to take a startup launched by a 
Japanese local university to success. In this sense, 
the technology transfer pattern in this case was 
different from that observed during 1970s and 
1980s, in which Europe and the U.S. created 
research breakthroughs, based on which Japan 
did the commercialization and formed profitable 
business.
However, in the case of OCT technology, from 
its invention to commercialization, Europe and 
the U.S. preceded Japan in commercialization by 
eight years and together hold a 90% share of the 
global market as of 2006. In order to make up for 
the loss, Japan not only needs to resolve issues 
of technology transfer but also needs to revise 
the screening process under the Pharmaceutical 
Affairs Law, a procedure specifically involving 
medicine-engineering collaboration. For instance, 
we should establish a physician-driven, highly 
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transparent system for clinical trials where safety 
can be ensured, by expanding the discretionary 
powers of physicians, professors and ethics 
committees in the clinical trial process so that 
they can collect cl inical data on their own 
responsibility in trials they consider safe.
Currently, intense competitions in product 
development are taking place, both domestically 
and internationally, involving second-generation, 
high - speed OCT technology. In this second 
generation, Japanese industry, academia and 
government have cooperated in exploiting the 
TLO Law appropriately, and Japan, which once 
lagged behind Europe and the U.S., has caught 
up with these countries and is ready to take the 
lead. OCT technology is advancing toward the 
third generation and, in addition to its current 
ophthalmologic application, is seeing wider use 
in, e.g. dermatology, dentistry, dental surgery, 
digestive surgery, and cardiovascular surgery, 
which is creating fresh global competition. Such 
global competition, involving collaboration 
between medicine and engineering in such areas 
as OCT innovation, is becoming more and more 
intense, not only in the technical realm but also 
in the area of transforming systems to support 
industry-academia-government collaboration and 
the operation of clinical trial systems. 
In the modern era of technology and business 
globalization, as the Ministry of Health, Labour 
and Welfare points out, if the Japanese legal 
system continues to consume an unnecessarily 
long time compared to other countries, Japanese 
companies will continue to receive approval for 
clinical trials or product sales in Europe or the 
U.S. before releasing the products in Japan. Such 
a situation would hinder the progress of Japanese 
medicine and destroy our self - reliance in the 
development of medical equipment.
In order to improve th is s ituat ion, and 
following the global trend in which the contents 
of clinical trials and clinical studies must be 
notified to a third-party organization beforehand, 
Japan must work on the establishment of a 
registration system for cl inical tr ials and a 
system for disclosing related information to 
the public and increase the budget to achieve 
this. Moreover, we must reinforce and expand 
medicine-engineering collaboration centers that 
integrate areas of medicine and engineering and, 
in the mid- and long - term, must establish an 
interdisciplinary human resource development 
system between humanities and science to foster 
the development of people who are qualified 
both in the law and medicine or engineering and 
who are capable of making decisions at higher 
levels so that we will be able to assign such 
people to the R&D of medical equipment or the 
operation of the legal system.
For further facilitation of the collaborative 
innovation between medicine and engineering 
in Japan, it will be more important than ever to 
further exploit the TLO Law and safely, swiftly 
and transparently implement the Pharmaceutical 
Affairs Law so that “those that need to be 
advanced are swiftly advanced, and those that 
need to be withdrawn are withdrawn at early 
stages.” It is urgent that we design a highly 
transparent, comprehensive strategy to promote 
collaborative innovation between medicine and 
engineering. Such policies are expected to result 
in further improvement in Japanese medicine and 
reinforcement of our global competitiveness in 
medical equipment development.
Acknowledgements
I would like to thank Mr. Naohiro Tanno, the 
ex-professor at Yamagata University, CEO Sumio 
Matsumura and Director Michiro Hasegawa of 
Microtomography Co., Ltd., Professor Toyohiko 
Yatagai of University of Tsukuba, Professor 
Masamitsu Haruna of Osaka University, Mr. 
Yasuhiro Suzuki and Mr. Narumasa Okada of 
the Health Policy Bureau, Ministry of Health, 
Labour and Welfare,  Doctor Yoshihiko Washimi 
of Teijin Limited and Doctor Masanori Kikuchi 
of the National Institute for Material Science for 
providing their valuable information and advice 
for preparing this manuscript.
References
[1] “Science and Technology Basic Plan” Cabinet 
Approval (March 28, 2006)
[2] Takahiro Fujimoto, “Japanese Philosophy of 
Manufacturing,” Nihon Keizai Shimbun, Inc., 
2004 (Japanese)
22
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
23
Q U A R T E R L Y  R E V I E W  N o . 2 2  /  J a n u a r y  2 0 0 7
[3] Hikaru Horiguchi, “Current Status and 
Direction of Medical Equipment Industry 
in Japan,” Forum 2006 held by the Science 
Council of Japan and the Japanese Society 
for Medical and Biological Engineering on 
January 23, 2006 at the University of Tokyo 
(Japanese)
[4] Yasuki Matsuo, “Summary of Japanese 
Government Life Science Budget Plan for 
Fiscal Year 2006, the Ministry of Education, 
Culture, Sports, Science and Technology,” 
ME For um 2006 held by the Sc ience 
Council of Japan and the Japanese Society 
for Medical and Biological Engineering on 
January 23, 2006 at the University of Tokyo 
(Japanese)
[5] Mamoru Tamura, “Current and Future 
States of Molecular Imaging by Light,” 
Kogaku, Vol. 35, No.2 (2006) ( Japanese)
[6] Naohiro Tanno, “Optical Coherence Tomography 
and its Application to Bioimaging,” Kogaku, 
Vol.28, No.3 (1999) (Japanese)
[7] Naohiro Tanno, Tsutomu Ichikawa, Akio 
Saeki: “Lightwave Reflection Measurement,” 
Japanese Patent No. 2010042 (applied for in 
1990) (Japanese)
[8] Yasuhiro Suzuki: “A New Horizon in Medical 
Equipment - Efforts by the Ministry of 
Health, Labour and Welfare,” ME Forum 
2006 held by the Science Council of Japan 
and the Japanese Society for Medical and 
Biological Engineering on January 23, 2006 
at University of Tokyo (Japanese)
[9] Shinji Chiba, Naohiro Tanno,“Backscattering 
Optical Heterodyne Tomography,”14th Laser 
Sensing Symposium (1991 (Japanese)
[10] Tan-no, T. Ichimura, T. Funaba, N. Anndo, 
and Y.  Odag i r i ,  “Opt ica l  mu lt i mode 
frequency-domain reflectometer,” Opt. Lett. 
(1994)
[11] Shoji Kishi, Kogaku, Vol.28, No.3 (1999)
[12] K i m i o  Ta t s u n o ,  “ R e c e n t  Tr e n d s  i n  
S e m i c o n d u c t o r  M i c r o f a b r i c a t i o n  
E qu ipment  Tech nolog y  —P ropos a l s  
for Industry -Academy Collaboration on 
Research and Development in Japan—,” 
Science and Technology Trends—Quarterly 
Review, National Institute of Science and 
Technology Policy, October 2004, No. 13
[13] D. Huang, E. A. Swanson, C. P. Lin, J. S. 
Schuman, W. G. Puliafito and J. G. Fujimoto: 
“Optical Coherence Tomography,” Science, 
254 (1991)
[14] E. A. Swanson, J. A. Izatt, M. R. Hee, D. Huang, 
C. P. Lin, J. S. Schuman, C. A. Puliafito and J. G. 
Fujimoto, “In vivo retinal imaging by optical 
coherence tomography,” Opt. Lett., Vol. 18 
(1993)
[15] C. A. Puliafito, M. R. Hee, J. S. Shuman 
and J. G. Fujimoto, “Optical Coherence 
Tomography of Ocular Diseases,” Slack 
Incorporated, NJ, (1996)
[16] http//pmda.go.jp/pdf/iryokiki.pdf/
[17] “Safety Guidebook on Laser,” supervised 
by the National Institute of Advanced 
Industrial Science and Technology, New 
Technology Communications ( Japanese)
[18] Kimitaka Kaga, “Arti f icial Cochlea and 
Artificial Auditory Brain Stem Implants,” 
ME Forum 2006 held by Science Council of 
Japan and Japanese Society for Medical and 
Biological Engineering on January 23, 2006 
at the University of Tokyo (Japanese)
[19] 1979 White Paper on Health and Welfare
 http://wwwhakusyo.mhlw.go.jp/wpdocs/hp
az197901/b0143.html
[20] “Thalidomide—Testimony of Scientists—,” 
edited by Motosaburo Masuyama, UP Sensho, 
University of Tokyo Press (1971) (Japanese)
[21] “Unprecedented Lawsuit on Adverse Drug 
Reactions: What We Should Learn from “the 
SMON Case,” Chuokoron- sha Inc. (1996) 
(Japanese)
[22] White Paper on the Labour Economy 2005
 http://www.mhlw.go.jp/wp/hakusho/kousei
/05/dl/2-9.pdf
[23] G. Hausler and M. W. Lindner, ““Coherence 
rader” and “spectral rader” —New tools for 
dermatological diagnosis—,” J. Biomed. Opt., 
3 (1998) 21-23.
[24] Y. Yasuno, M. Nakama, Y. Sutoh, M. Itoh, 
M. Mori, and T. Yatagai, “Optical coherence 
tomography by spectral interferometric joint 
transform correlator,” Opt. Commun., Vol. 
186 (2000)
[25] Masahide Itoh, Yoshiaki Yasuno, Toyohiko 
24
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
Yatagai, “Fourier Domain Optical Coherence 
Tomography,” Japanese Journal of Visual 
Science, Vol. 23, No.3 ( Journal of the 
Japanese Society of Opthalmological Optics), 
(2005) (Japanese)
[26] Masamitsu Haruna, “Medical Application 
and Technological Development of Optical 
Coherence Tomography (OCT),” Optics 
Design Group (Optical Society of Japan), 
34th Study Meeting held at University of 
Tokyo in 2006 (Japanese)
[27] M. Ohmi, K. Nohara, Y. Ueda, T. Fuji and M. 
Haruna,“Dynamic observation of sweat glands 
of human finger tip using all -optical -fiber 
high-speed optical coherence tomography,” 
Jpn. J. Appl. Phys., Vol. 44, No. 26, pp. 
L854-L856 (2005).
Kimio TATSUNO, PhD
Head, Information and Communications Research Unit
D. Eng. He was formerly involved in the R&D on optical disks, fiber-optic communication, and diode 
laser-related instruments at the Central Research Laboratory, Hitachi Ltd.  Currently, he proposes 
technology innovation, and studies science and technology trends at NISTEP.
Membership: JSAP, IEICE, OSA.
(Original Japanese version: published in July 2006)
